How much funding has CustoMED raised?

CustoMED has raised $6M in total funding. Key investors include Longevity Venture Partners; Varana Capital; Flag Capital; Israel Innovation Authority; Avishai Abrahami; Unnamed Orthopedic Implant Company.

Who is the CEO of CustoMED?

Yun Nguyen is the CEO of CustoMED. The company was founded in 2023.

Where is CustoMED located?

CustoMED is headquartered in Ramat Gan, Israel.

What funding stage is CustoMED at?

CustoMED is currently at the Early Stage stage.

How many employees does CustoMED have?

CustoMED has approximately 11-50 employees.

CustoMED

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

SoftwareRamat Gan, IsraelFounded 2023· One of 350 Software companies tracked by AMPulse

Develops an AI-driven cloud platform that automates the design and 3D printing of patient-specific orthopedic surgical instruments and implants, reducing production time from weeks to minutes.

CEO / Founder: Yun Nguyen
Team Size: 11-50
Stage: Early Stage
Total Funding: $6M
Latest Round: Seed
Key Investors: Longevity Venture Partners; Varana Capital; Flag Capital; Israel Innovation Authority; Avishai Abrahami; Unnamed Orthopedic Implant Company

Technology & Products

Key Products

AI-driven orthopedic platform; Cloud-based surgical planning software; 3D printed patient-specific surgical guides; 3D printed patient-specific implants

Technological Advantage

Proprietary AI algorithms automate the entire design-to-print workflow for orthopedic devices, protected by trade secrets and clinical validation from leading medical institutions.

Differentiation

Value Proposition

Reduces manual design bottlenecks by 90% and operating room time by 30% through automated AI workflows, enabling scalable personalized orthopedics with faster, more precise surgeries.

How They Differentiate

Fully automated AI-driven workflow reduces design time from hours to minutes vs. Materialise's manual-intensive processes; focuses exclusively on orthopedic applications vs. broader medical 3D printing from 3D Systems and Stratasys.

Market & Competition

Target Customers

Orthopedic surgeons, hospitals, surgical centers

Industry Verticals

Medical; Healthcare

Competitors

Materialise; 3D Systems; Stratasys

Growth & Milestones

Growth Metrics

CustoMED has grown to serve over 100 hospitals globally, with reported revenue growth of 200% year-over-year in recent years and expansion into new markets such as Europe and Asia.

Major Milestones

$6M seed funding round completed in October 2025; Platform development from Sheba Medical Center's 3D Printing & Innovation Lab

Notable Customers

Sheba Medical Center (originating hospital), hundreds of successful surgeries performed worldwide

https://www.customed.ai

Recent coverage of CustoMED

CustoMED is scaling personalized orthopedics by automating the 3D printing of patient-specific instruments.Feb 13, 2026

Why this company matters

CustoMED occupies a niche at the intersection of AI-driven surgical planning and metal additive manufacturing for orthopedics. Its cloud platform converts pre-operative imaging into 3D printable surgical guides and implants, targeting a bottleneck that has limited personalized orthopedics to high-cost, manual workflows. The company originated from Sheba Medical Center's 3D Printing & Innovation Lab, giving it a clinical foundation from inception.

The core technology is a proprietary AI engine that automates the entire design-to-print pipeline for orthopedic devices. By ingesting CT or MRI scans, the software generates patient-specific surgical guides and implants optimized for metal LPBF or other metal AM processes. CustoMED claims this reduces manual design time by 90% and cuts operating room time by 30%, enabling hospitals to scale personalized procedures without adding surgical planning staff.

CustoMED's primary customers are orthopedic surgeons and hospitals, with over 100 hospitals served globally and hundreds of successful surgeries performed. The platform is used for both surgical guides and permanent implants, competing with manual-intensive offerings from Materialise and broader medical 3D printing portfolios from 3D Systems and Stratasys. CustoMED differentiates by focusing exclusively on orthopedics and automating steps that competitors still handle manually.

The company raised a $6M seed round in October 2025 from Longevity Venture Partners, Varana Capital, Flag Capital, and the Israel Innovation Authority, among others. Reported revenue growth of 200% year-over-year and expansion into Europe and Asia suggest early traction, but the company remains in a niche where clinical validation and regulatory clearance are critical moats. Its reliance on trade secrets rather than a broad patent portfolio may pose a risk as larger competitors invest in similar AI workflows.